Publications
[73] Herzog CR*, Zhang J*, Feng X*, Dang TT, Yu X, Huang J, Fang F, Gao H, Yu X, Wang Y, Han R, Liu Y, Cornetta K, Xiao W, Xu W (2025) Bioinformatic analysis of the genetic basis of differential AAV production capability of 293 variants. Human Gene Therapy doi: 10.1089/hum.2025.002. Full Text
[72] Liu D, Cao D, Han R*. (2025) Recent advances in therapeutic gene editing technologies. Molecular Therapy doi: 10.1016/j.ymthe.2025.03.026. Full Text
[71] Li S, Zhang C, Han R*. (2025) An oversized AAV8 vector to deliver CPS1. Molecular Therapy - Nucleic Acids 36: 102504. Full Text
[70] Koike T, Koike Y, Guo Y, Yang D, Song J, Xu J, Zhao X, Zhu T, Li R, Wen B, Sun D, Rom O, Han R, Fan J, Garcia-Barrio MT, Zhang J, Chen YE. (2025) IDOL Deficiency Inhibits Cholesterol-Rich Diet-Induced Atherosclerosis in Rabbits. Arteriosclerosis, Thrombosis, and Vascular Biology doi: 10.1161/ATVBAHA.125.322417. Full Text
[69] Tsai L-K, Han R, Yang D, Chen YE, Zhang J, Xu J (2025) Promotion or inhibition? This is a question in gene editing. Molecular Therapy doi: 10.1016/j.ymthe.2025.01.014. Full Text
[68] Tran NT, Han R*. (2024) Rapidly Evolving Genome and Epigenome Editing Technologies. Molecular Therapy 32: 2803-2806. Full Text
[67] Zhou R, Zhang C, Xiao W, Herzog RW, Han R*. (2024) Systemic Delivery of Full-Length Dystrophin in Duchenne Muscular Dystrophy Mice. Nature Communications 15(1): 6141. Full Text
[66] Gandhi S*, Sweeney HL, Hart CC, Han R, Perry CGR* (2024) Mitochondria in Duchenne Muscular Dystrophy-induced Cardiomyopathy: A Prospective Therapeutic Target to Improve Treatment Response. Cells 13(14): 1168. Full Text
[65] Li S, Han R*. (2024) Targeting miR-25 to Alleviate DMD-Related Muscle Dysfunction. Molecular Therapy - Nucleic Acids 35: 102238. Full Text
[64] Zhang C, Zhou Y, Han R*. (2024) Base editing in humanized dystrophic mice. Molecular Therapy - Nucleic Acids 35: 102185. Full Text
[63] Han R*. (2024) Hit-and-run epigenome editing durably lowers cholesterol in mice. Molecular Therapy 32: 1190-1191. Full Text
[62] Han R*. (2023) First in vivo base-editing trial shows promise. Molecular Therapy 32: 1-2. Full Text
[61] Li H, Wang P, Zhang C, Zuo Y, Zhou Y, Han R*. (2023) Defective BVES-mediated feedback control of cAMP in muscular dystrophy. Nature Communications 14: 1785. Full Text
[60] Zuo Y, Zhang C, Zhou Y, Li H, Xiao W, Herzog RW, Xu J, Zhang J, Chen EY, Han R*. (2023) Liver-specific in vivo base editing of Angptl3 via AAV delivery efficiently lowers blood lipid levels in mice. Cell & Bioscience 13: 109. Full Text
[59] Wang P, Li H, Zhu M, Han RY, Guo S, Han R*. (2022) Correction of DMD in human iPSC-derived cardiomyocytes by base editing-induced exon skipping. Molecular Therapy - Methods & Clinical Development 28: 40-50. Full Text
[58] Li H, Wang P, Hsu E, Pinckard KM, Stanford KI and Han R*. (2022) Systemic AAV9.BVES Delivery Ameliorates Muscular Dystrophy in a Mouse Model of LGMDR25. Molecular Therapy 31(2): 398-408. Full Text
[57] Zou X, Ouyang H, Lin F, Zhang H, Yang Y, Pang D, Han R*, Tang X*. (2022) MYBPC3 deficiency in cardiac fibroblasts drives their activation and contributes to fibrosis. Cell Death & Disease 13(11): 948. Full Text
[56] Li H, Zhang L, Zhang L and Han R*. (2022) Autophagy in striated muscle diseases. Frontiers in Cardiovascular Medicine doi: 10.3389/fcvm.2022.1000067. Full Text
[55] Zhang M, Urabe G, Ozer HG, Xie X, Webb A, Shirasu T, Li J, Han R, Kent KC, Wang B and Guo LW. (2022) Angioplasty induces epigenomic remodeling in injured arteries. Life Science Alliance 5: e202101114. Full Text
[54] Li H, Xu L, Gao Y, Zuo Y, Yang Z, Zhao L, Chen Z, Guo J, Han R*. (2021) BVES Is a Novel Interactor of ANO5 and Regulates Myoblast Differentiation. Cell & Bioscience 11(1): 222. Full Text
| Next | Last |